Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07396584 | A Phase I/Ⅱa Study of HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor | PHASE1/PHASE2 | NOT YET_RECRUITING | 186 | — | — | Feb 1, 2026 | Jan 1, 2029 | Feb 8, 2026 | - | — |
| Name | Type | Description |
|---|---|---|
| HMPL-A580 | DRUG | Part A(Phase I) Dose Escalation Enrolled participants will receive HMPL-A580 treatment in a dose escalation setting initially at 6 predefined dose levels. |